Abstract
Class C G protein-coupled receptors encompass a range of promising therapeutic targets for a variety of diseases, yet to date only two members of this sub-family of GPCRs have been drugged. Recent advances in structural biology have revealed the X-ray crystallographic structures of allosteric ligands bound to two Class C metabotropic glutamate (mGlu) receptors, mGlu1 and mGlu5. Herein, we review how this information can be leveraged to help understand some of the historical challenges of mGlu receptor allosteric modulator drug discovery, and discuss how the structural enablement can be prospectively used for structurebased drug discovery approaches across Class C GPCR targets in general.
Keywords: Allosteric, CNS, Crystallography, Glutamate, GPCR, Modulator.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Potential for the Rational Design of Allosteric Modulators of Class C GPCRs
Volume: 17 Issue: 1
Author(s): John A. Christopher, Andrew S. Doré and Benjamin G. Tehan
Affiliation:
Keywords: Allosteric, CNS, Crystallography, Glutamate, GPCR, Modulator.
Abstract: Class C G protein-coupled receptors encompass a range of promising therapeutic targets for a variety of diseases, yet to date only two members of this sub-family of GPCRs have been drugged. Recent advances in structural biology have revealed the X-ray crystallographic structures of allosteric ligands bound to two Class C metabotropic glutamate (mGlu) receptors, mGlu1 and mGlu5. Herein, we review how this information can be leveraged to help understand some of the historical challenges of mGlu receptor allosteric modulator drug discovery, and discuss how the structural enablement can be prospectively used for structurebased drug discovery approaches across Class C GPCR targets in general.
Export Options
About this article
Cite this article as:
Christopher A. John, Doré S. Andrew and Tehan G. Benjamin, Potential for the Rational Design of Allosteric Modulators of Class C GPCRs, Current Topics in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1568026616666160719165922
DOI https://dx.doi.org/10.2174/1568026616666160719165922 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overview of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Recent Medicinal Chemistry Studies for Multitarget Agents-Part II
Current Drug Targets Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Rhinosinusitis in the Pediatric Patient with Cystic Fibrosis
Current Pediatric Reviews Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease
Current Psychopharmacology Curcumin Activates Erythrocyte Membrane Acetylcholinesterase
Letters in Drug Design & Discovery Multitarget Network Strategies to Influence Memory and Forgetting: The Ras/Mapk Pathway as a Novel Option
Mini-Reviews in Medicinal Chemistry Attention Deficit and Hyperactivity Disorder: Controversies of Diagnosis and Safety of Pharmacological and Nonpharmacological Treatment
Current Drug Safety A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia
Current Drug Targets Preface [Hot topic: Potential Therapeutic Agents for Parkinsons Disease (Executive Editor: Masato Asanuma)]
Current Pharmaceutical Design AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies
Current Pharmacogenomics and Personalized Medicine Cyclic AMP-Specific Phosphodiesterase-4 as a Target for the Development of Antidepressant Drugs
Current Pharmaceutical Design Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review
Protein & Peptide Letters Subject Index to Volume 3
Current Medicinal Chemistry - Central Nervous System Agents Mobile Phone Text Message Interventions in Psychiatry - What are the Possibilities?
Current Psychiatry Reviews <i>Withania somnifera</i> in Neurological Disorders: Ethnopharmacological Evidence, Mechanism of Action and its Progress in Delivery Systems
Current Drug Metabolism